131 related articles for article (PubMed ID: 10842262)
1. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis.
Armon C; Graves MC; Moses D; Forté DK; Sepulveda L; Darby SM; Smith RA
Muscle Nerve; 2000 Jun; 23(6):874-82. PubMed ID: 10842262
[TBL] [Abstract][Full Text] [Related]
2. Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials.
Armon C; Moses D
J Neurol Sci; 1998 Oct; 160 Suppl 1():S37-41. PubMed ID: 9851647
[TBL] [Abstract][Full Text] [Related]
3. Motor unit number estimate-based rates of progression of ALS predict patient survival.
Armon C; Brandstater ME
Muscle Nerve; 1999 Nov; 22(11):1571-5. PubMed ID: 10514236
[TBL] [Abstract][Full Text] [Related]
4. Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey.
Clavelou P; Blanquet M; Peyrol F; Ouchchane L; Gerbaud L
J Neurol Sci; 2013 Aug; 331(1-2):126-31. PubMed ID: 23809193
[TBL] [Abstract][Full Text] [Related]
5. Comparison of slow and forced vital capacities on ability to predict survival in ALS.
Pinto S; de Carvalho M
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Nov; 18(7-8):528-533. PubMed ID: 28741375
[TBL] [Abstract][Full Text] [Related]
6. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
[TBL] [Abstract][Full Text] [Related]
7. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.
Cudkowicz ME; Shefner JM; Schoenfeld DA; Brown RH; Johnson H; Qureshi M; Jacobs M; Rothstein JD; Appel SH; Pascuzzi RM; Heiman-Patterson TD; Donofrio PD; David WS; Russell JA; Tandan R; Pioro EP; Felice KJ; Rosenfeld J; Mandler RN; Sachs GM; Bradley WG; Raynor EM; Baquis GD; Belsh JM; Novella S; Goldstein J; Hulihan J;
Neurology; 2003 Aug; 61(4):456-64. PubMed ID: 12939417
[TBL] [Abstract][Full Text] [Related]
9. Functional outcome measures as clinical trial endpoints in ALS.
Traynor BJ; Zhang H; Shefner JM; Schoenfeld D; Cudkowicz ME;
Neurology; 2004 Nov; 63(10):1933-5. PubMed ID: 15557515
[TBL] [Abstract][Full Text] [Related]
10. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
[TBL] [Abstract][Full Text] [Related]
11. [Revised amyotrophic lateral sclerosis functional rating scale at time of diagnosis predicts survival time in amyotrophic lateral sclerosis].
Liu XX; Fan DS; Zhang J; Zhang S; Zheng JY
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(35):2472-5. PubMed ID: 20137433
[TBL] [Abstract][Full Text] [Related]
12. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2012 Dec; 12():CD005225. PubMed ID: 23235621
[TBL] [Abstract][Full Text] [Related]
13. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group.
Stambler N; Charatan M; Cedarbaum JM
Neurology; 1998 Jan; 50(1):66-72. PubMed ID: 9443459
[TBL] [Abstract][Full Text] [Related]
14. Complex fasciculation potentials and survival in amyotrophic lateral sclerosis.
Shimizu T; Fujimaki Y; Nakatani-Enomoto S; Matsubara S; Watabe K; Rossini PM; Ugawa Y
Clin Neurophysiol; 2014 May; 125(5):1059-64. PubMed ID: 24345314
[TBL] [Abstract][Full Text] [Related]
15. Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis.
Baumann F; Henderson RD; Morrison SC; Brown M; Hutchinson N; Douglas JA; Robinson PJ; McCombe PA
Amyotroph Lateral Scler; 2010; 11(1-2):194-202. PubMed ID: 19452343
[TBL] [Abstract][Full Text] [Related]
16. Amyotrophic lateral sclerosis: early predictors of prolonged survival.
Czaplinski A; Yen AA; Appel SH
J Neurol; 2006 Nov; 253(11):1428-36. PubMed ID: 16773270
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design.
Schmidt EP; Drachman DB; Wiener CM; Clawson L; Kimball R; Lechtzin N
Muscle Nerve; 2006 Jan; 33(1):127-32. PubMed ID: 16258948
[TBL] [Abstract][Full Text] [Related]
18. Phrenic nerve studies predict survival in amyotrophic lateral sclerosis.
Pinto S; Pinto A; de Carvalho M
Clin Neurophysiol; 2012 Dec; 123(12):2454-9. PubMed ID: 22762911
[TBL] [Abstract][Full Text] [Related]
19. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing?
Czaplinski A; Yen AA; Simpson EP; Appel SH
Arch Neurol; 2006 Aug; 63(8):1139-43. PubMed ID: 16908741
[TBL] [Abstract][Full Text] [Related]
20. Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis.
Capozzo R; Quaranta VN; Pellegrini F; Fontana A; Copetti M; Carratù P; Panza F; Cassano A; Falcone VA; Tortelli R; Cortese R; Simone IL; Resta O; Logroscino G
J Neurol; 2015 Mar; 262(3):593-603. PubMed ID: 25522696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
